S
Sara E. Reese
Publications - 20
Citations - 1014
Sara E. Reese is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 2 citations.
Papers
More filters
Journal ArticleDOI
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Jill M. Ferdinands,S. Rao,Brian E. Dixon,Patrick K. Mitchell,Malini B. DeSilva,Stephanie A. Irving,Ned Lewis,Karthik Natarajan,Edward Stenehjem,Shaun J. Grannis,Jungmi Han,Charlene McEvoy,Toan C. Ong,Allison L. Naleway,Sara E. Reese,Peter J. Embi,Kristin Dascomb,Nicola P. Klein,E. Griggs,D. Konatham,Anupam B. Kharbanda,Duck-Hye Yang,William F. Fadel,Nancy Grisel,Kristin Goddard,Palak Patel,I-Chia Liao,Rebecca Birch,Nimish Valvi,Sue Reynolds,Julie Arndorfer,Ousseny Zerbo,M. Dickerson,Kempapura Murthy,Jeremiah Williams,Catherine H Bozio,Lenee Blanton,Jennifer R. Verani,Stephanie J. Schrag,Alexandra F. Dalton,Mehiret Wondimu,Ruth Link-Gelles,Eduardo Azziz-Baumgartner,Michelle A. Barron,Manjusha Gaglani,Mark Thompson,Bruce Fireman +46 more
TL;DR: VE after receipt of a third dose was higher than that after a second dose; however, VE waned with increasing time since vaccination, and VE was generally higher for protection against hospitalizations than against ED/UC visits.
Journal ArticleDOI
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Mark Thompson,Karthik Natarajan,Stephanie A. Irving,Elizabeth Rowley,E. Griggs,Manjusha Gaglani,Nicola P. Klein,Shaun J. Grannis,Malini B. DeSilva,Edward Stenehjem,Sara E. Reese,M. Dickerson,Allison L. Naleway,Jungmi Han,D. Konatham,Charlene McEvoy,S. Rao,Brian E. Dixon,Kristin Dascomb,Ned Lewis,M. Levy,Palak Patel,I-Chia Liao,Anupam B. Kharbanda,Michelle A. Barron,William F. Fadel,Nancy Grisel,Kristin Goddard,Duck-Hye Yang,Mehiret Wondimu,Kempapura Murthy,Nimish Valvi,Julie Arndorfer,Bruce Fireman,M. Dunne,Peter J. Embi,Eduardo Azziz-Baumgartner,Ousseny Zerbo,Catherine H Bozio,Sue Reynolds,Jill M. Ferdinands,Jeremiah Williams,Ruth Link-Gelles,Stephanie J. Schrag,Jennifer R. Verani,Sarah Ball,Toan C. Ong +46 more
TL;DR: The highest estimates of VE against COVID-19-associated ED and UC encounters or hospitalizations during both Delta- and Omicron-predominant periods were among adults who received a third dose of mRNA vaccine, and all unvaccinated persons should get vaccinated as soon as possible.
Journal ArticleDOI
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022
Nicola P. Klein,Melissa S. Stockwell,Maria Demarco,Manjusha Gaglani,Anupam B. Kharbanda,Stephanie A. Irving,S. Rao,Shaun J. Grannis,Kristin Dascomb,Kempapura Murthy,Elizabeth Rowley,Alexandra F. Dalton,Malini B. DeSilva,Brian E. Dixon,Karthik Natarajan,Edward Stenehjem,Allison L. Naleway,Ned Lewis,Toan C. Ong,Palak Patel,D. Konatham,Peter J. Embi,Sara E. Reese,Jungmi Han,Nancy Grisel,Kristin Goddard,Michelle A. Barron,M. Dickerson,I-Chia Liao,William F. Fadel,Duck-Hye Yang,Julie Arndorfer,Bruce Fireman,E. Griggs,Nimish Valvi,C. Hallowell,Ousseny Zerbo,Sue Reynolds,Jill M. Ferdinands,Mehiret Wondimu,Jeremiah Williams,Catherine H Bozio,Ruth Link-Gelles,Eduardo Azziz-Baumgartner,Stephanie J. Schrag,Mark Thompson,Jennifer R. Verani +46 more
TL;DR: VE against laboratory-confirmed COVID-19-associated hospitalization among children aged 5-11 years was 74% 14-67 days after dose 2, with wide CIs that included zero, and in adolescents aged 16-17 years, VE during the Omicron predominant period increased to 81% ≥7 days after a third booster dose.
Journal ArticleDOI
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022
Ruth Link-Gelles,M. Levy,Manjusha Gaglani,Stephanie A. Irving,Melissa S. Stockwell,Kristin Dascomb,Malini B. DeSilva,Sara E. Reese,I-Chia Liao,Toan C. Ong,Shaun J. Grannis,Charlene McEvoy,Palak Patel,Nicola P. Klein,E. Hartmann,Edward Stenehjem,Karthik Natarajan,Allison L. Naleway,Kempapura Murthy,S. Rao,Brian E. Dixon,Anupam B. Kharbanda,Akintunde Akinseye,M. Dickerson,Ned Lewis,Nancy Grisel,Jungmi Han,Michelle A. Barron,William F. Fadel,M. Dunne,Kristin Goddard,Julie Arndorfer,D. Konatham,Nimish Valvi,Jon Currey,Bruce Fireman,Chandni Raiyani,Ousseny Zerbo,C. Sloan-Aagard,Sarah Ball,Mark Thompson,Mark W Tenforde +41 more
TL;DR: Estimates of COVID-19 vaccine effectiveness (VE) can be reduced by newly emerging variants or sublineages that evade vaccine-induced immunity, protection from previous SARS-CoV-2 infection in unvaccinated persons (2), or increasing time since vaccination (3).
Journal ArticleDOI
Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study
Jill M. Ferdinands,S. Rao,Brian E. Dixon,Patrick K. Mitchell,Malini B. DeSilva,Stephanie A. Irving,Ned Lewis,Karthik Natarajan,Edward Stenehjem,Shaun J. Grannis,Jungmi Han,Charlene McEvoy,Toan C. Ong,Allison L. Naleway,Sara E. Reese,Peter J. Embi,Kristin Dascomb,Nicola P. Klein,E. Griggs,I-Chia Liao,Duck-Hye Yang,William F. Fadel,Nancy Grisel,Kristin Goddard,Palak Patel,Kempapura Murthy,Rebecca Birch,Nimish Valvi,Julie Arndorfer,Ousseny Zerbo,M. Dickerson,Chandni Raiyani,Jeremiah Williams,Catherine H Bozio,Lenee Blanton,Ruth Link-Gelles,Michelle A. Barron,Manjusha Gaglani,Mark Thompson,Bruce Fireman +39 more
TL;DR: Effectiveness of mRNA vaccines against moderate and severe covid-19 waned with time after vaccination, and recommendations for a booster dose after a primary series and consideration of additional booster doses are supported.